A Systematic Review and Meta-analysis of the Effect of Intravitreal VEGF Inhibitors on Cardiorenal Outcomes

Overview

Journal Nephrol Dial Transplant

Publisher Oxford University Press

Specialties General Surgery
Nephrology

Date 2022 Nov 1

PMID 36318455

Authors

Jennifer S Lees

Stephen J H Dobbin

Benjamin M P Elyan

David F Gilmour

Laurie P Tomlinson

Ninian N Lang

Patrick B Mark

Affiliations

Soon will be listed here.

Abstract

Background: Vascular endothelial growth factor inhibitors (VEGFis) have transformed the treatment of many retinal diseases, including diabetic maculopathy. Increasing evidence supports systemic absorption of intravitreal VEGFi and development of significant cardiorenal side effects.

Methods: We conducted a systematic review and meta-analysis (PROSPERO: CRD42020189037) of randomised controlled trials of intravitreal VEGFi treatments (bevacizumab, ranibizumab and aflibercept) for any eye disease. Outcomes of interest were cardiorenal side effects (hypertension, proteinuria, kidney function decline and heart failure). Fixed effects meta-analyses were conducted where possible.

Results: There were 78 trials (81 comparisons; 13 175 participants) that met the criteria for inclusion: 47% were trials in diabetic eye disease. Hypertension (29 trials; 8570 participants) was equally common in VEGFi and control groups {7.3 versus 5.4%; relative risk [RR] 1.08 [95% confidence interval (CI) 0.91-1.28]}. New or worsening heart failure (10 trials; 3384 participants) had a similar incidence in VEGFi and control groups [RR 1.03 (95% CI 0.70-1.51)]. Proteinuria (5 trials; 1902 participants) was detectable in some VEGFi-treated participants (0.2%) but not controls [0.0%; RR 4.43 (95% CI 0.49-40.0)]. Kidney function decline (9 trials; 3471 participants) was similar in VEGFi and control groups. In participants with diabetic eye disease, the risk of all-cause mortality was higher in VEGFi-treated participants [RR 1.62 (95% CI 1.04-2.46)].

Conclusion: In trials of intravitreal VEGFi, we did not identify an increased risk of cardiorenal outcomes, although these outcomes were reported in only a minority of cases. There was an increased risk of death in VEGFi-treated participants with diabetic eye disease. Additional scrutiny of post-licensing observational data may improve the recognition of safety concerns in VEGFi-treated patients.

Citing Articles

Case report: heart failure related to intravitreal injection of anti-VEGF.

Sui Y, Zhao Y, Zhou N, Sun H, Sun Y, Liu J BMC Cardiovasc Disord. 2024; 24(1):418.

PMID: 39135154 PMC: 11318321. DOI: 10.1186/s12872-024-04095-4.

Cai C, Nishimura A, Bowring M, Westlund E, Tran D, Ng J Ophthalmol Retina. 2024; 8(8):733-743.

PMID: 38519026 PMC: 11298306. DOI: 10.1016/j.oret.2024.03.014.

Should patient enrollment criteria for anti-VEGF phase III trials be reconsidered.

Hanhart J, Jeon S, Tuuminen R J Diabetes. 2023; 15(10):911-912.

PMID: 37731062 PMC: 10590675. DOI: 10.1111/1753-0407.13468.

GFR slope as a surrogate marker for future kidney failure.

Lees J, Mark P Nat Rev Nephrol. 2023; 19(10):625-626.

PMID: 37495682 DOI: 10.1038/s41581-023-00748-3.

References

Bae S, Heo J, Kim C, Kim T, Shin J, Lee J . Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Ophthalmology. 2013; 121(2):558-65. DOI: 10.1016/j.ophtha.2013.09.024. View

Nguyen Q, Sepah Y, Berger B, Brown D, Do D, Garcia-Hernandez A . Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema. Int J Retina Vitreous. 2019; 5:28. PMC: 6670150. DOI: 10.1186/s40942-019-0178-7. View

Korobelnik J, Do D, Schmidt-Erfurth U, Boyer D, Holz F, Heier J . Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014; 121(11):2247-54. DOI: 10.1016/j.ophtha.2014.05.006. View

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

Callanan D, Loewenstein A, Patel S, Massin P, Corcostegui B, Li X . A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2016; 255(3):463-473. DOI: 10.1007/s00417-016-3472-1. View

Solomon S, Lindsley K, Vedula S, Krzystolik M, Hawkins B . Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019; 3:CD005139. PMC: 6419319. DOI: 10.1002/14651858.CD005139.pub4. View

Dobbin S, Cameron A, Petrie M, Jones R, Touyz R, Lang N . Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart. 2018; 104(24):1995-2002. PMC: 6268130. DOI: 10.1136/heartjnl-2018-313726. View

Ding X, Li J, Hu X, Yu S, Pan J, Tang S . Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina. 2011; 31(5):838-45. DOI: 10.1097/IAE.0b013e3181f4420d. View

Brown D, Campochiaro P, Singh R, Li Z, Gray S, Saroj N . Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6):1124-1133.e1. DOI: 10.1016/j.ophtha.2010.02.022. View

10.

Avery R, Gordon G . Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2015; 134(1):21-9. DOI: 10.1001/jamaophthalmol.2015.4070. View

11.

Hanna R, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I . Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019; 96(3):572-580. DOI: 10.1016/j.kint.2019.02.042. View

12.

Thulliez M, Angoulvant D, Le Lez M, Jonville-Bera A, Pisella P, Gueyffier F . Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol. 2014; 132(11):1317-26. DOI: 10.1001/jamaophthalmol.2014.2333. View

13.

Soheilian M, Garfami K, Ramezani A, Yaseri M, Peyman G . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina. 2012; 32(2):314-21. DOI: 10.1097/IAE.0b013e31822f55de. View

14.

. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 2013; 131(3):283-93. PMC: 4217122. DOI: 10.1001/jamaophthalmol.2013.2015. View

15.

Gale J, Berger B, Gilbert S, Popa S, Sultan M, Schachar R . A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018; 59(6):2659-2669. DOI: 10.1167/iovs.17-22731. View

16.

Glassman A, Liu D, Jampol L, Sun J . Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018; 59(3):1199-1205. PMC: 5837671. DOI: 10.1167/iovs.17-22853. View

17.

Kriechbaum K, Prager S, Mylonas G, Scholda C, Rainer G, Funk M . Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye (Lond). 2013; 28(1):9-15. PMC: 3890767. DOI: 10.1038/eye.2013.242. View

18.

Reibaldi M, Fallico M, Avitabile T, Bonfiglio V, Russo A, Castellino N . Risk of Death Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2019; 138(1):50-57. PMC: 6902107. DOI: 10.1001/jamaophthalmol.2019.4636. View

19.

Virgili G, Parravano M, Evans J, Gordon I, Lucenteforte E . Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017; 6:CD007419. PMC: 6481463. DOI: 10.1002/14651858.CD007419.pub5. View

20.

Preti R, Vasquez Ramirez L, Monteiro M, Carra M, Pelayes D, Takahashi W . Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial. Br J Ophthalmol. 2013; 97(7):885-9. DOI: 10.1136/bjophthalmol-2012-302675. View